Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
about
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaHigh-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsCurrent challenges and novel treatment strategies in double hit lymphomasG-CSF and GM-CSF in NeutropeniaLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsTreatment of diffuse large B cell lymphomaThe copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphomaDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.T-cell lymphomas, a challenging disease: types, treatments, and future.MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European CaucasiansHigh dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Growth factor use in medication-induced hematologic toxicity.NHL (diffuse large B cell lymphoma)Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies.High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials.Toward a Biology-Driven Treatment Strategy for Peripheral T-cell LymphomaA combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?NHL (diffuse large B-cell lymphoma).Recent advances in the treatment of B-cell lymphomaA new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugMoving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trialsA biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration.Modelling chemotherapy effects on granulopoiesis.Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsMerging concepts - coupling an agent-based model of hematopoietic stem cells with an ODE model of granulopoiesis.A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaDifferential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials.Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathyA Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
P2860
Q24240753-251C93E1-E899-4A76-B690-1679089EAD59Q24242089-14F856D3-9320-4206-B476-2294F171EC17Q26770385-9BCD3CB5-9463-421F-AFE0-D2C2644C064DQ26800954-F3AED502-CAA8-4877-AC8F-170A850F16B4Q26849243-FD8E6CFF-430F-4F30-BB9B-5ADD49194A9AQ27006062-892EB18F-5675-4D9D-9A9E-521141223451Q28389285-F72725FC-9CD2-479A-B9D9-B4287A23E2FCQ30235296-2EEC9ABA-0F50-46D8-8519-22ED6AEB7835Q30244553-36078156-F3C6-49D8-BA56-E20DE59EC3FFQ33330490-757A48FD-8095-424D-9708-5437EBDA721AQ33375173-AD2E1769-58CB-4AFA-BF20-C642F7F24582Q33417812-D9CB2BAD-94CF-4040-9164-EF8FE862EE42Q33446735-E5DB9AC9-10C3-4C56-B160-0C3D281FB463Q33585882-498413EC-3C67-4C65-AEF1-E0EC397B8788Q33612733-7261D217-95B4-4974-84BE-C004E31E74F9Q33626490-DDDC3E39-4EF1-4F2E-8FC3-23E363E8CBE7Q33632239-BBB56E38-C2D8-438D-A9C8-22240D007F49Q33670421-07118A33-A448-4013-8774-AF1B48CB6D2FQ33712928-1ED5CD10-FF75-4AB4-AF6B-A71F25CA3209Q33756369-63EFDCEF-8DC5-4B28-A531-CB5846F9A177Q33846734-3B1A7A25-B94F-4208-9D2A-8B9803B3BB20Q34062432-4130A2E2-F060-4355-A0AD-250C02C9425BQ34065271-0CB971FB-C44B-47C1-B32F-8B7F9ADDFB28Q34269228-34698D85-B5B6-445D-AFCE-AA79E95114C3Q34352408-3520FD10-0BA4-4B2B-9764-4021ABE4ABD5Q34766672-54C8345D-C2AD-4C3B-9694-DCC69DC5A0CEQ34996295-34D490A7-3B46-4214-8FDF-67983A7E1FAEQ35004750-A87CB7DC-A69D-49D4-B3E4-9644EFBA82C5Q35030415-3E869908-9E97-4471-A173-090055A353AEQ35086595-148B01AE-DEAD-4B34-9F64-530B1EDF23ABQ35091598-889424D5-7BA5-48B3-B169-1EA54774C7EDQ35208183-DB5A32DA-61B9-4DB5-93D2-A39AA749B172Q35483564-B17A8D35-F5C6-447D-9FD8-062B83B9D585Q35536636-DE840581-E7B2-44E9-B427-82CAD8D7725EQ35551019-713BCAD0-C837-49D4-9E70-F5AF4514FF41Q35613669-04957C02-0CCD-4715-A86B-A14D28B71927Q35638549-719478BA-F8C7-4CD5-8987-38BCDCB2D6F1Q35673260-CFEEEBD4-1E54-497A-9E16-6E1D6F0C9670Q35930640-7A41C5B7-1ADB-4D12-B7EE-EC2F9D4021C7Q35967278-C49EF873-CC6A-4F72-B30E-CE5A1E583B4C
P2860
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Two-weekly or 3-weekly CHOP ch ...... he NHL-B2 trial of the DSHNHL.
@en
Two-weekly or 3-weekly CHOP ch ...... he NHL-B2 trial of the DSHNHL.
@nl
type
label
Two-weekly or 3-weekly CHOP ch ...... he NHL-B2 trial of the DSHNHL.
@en
Two-weekly or 3-weekly CHOP ch ...... he NHL-B2 trial of the DSHNHL.
@nl
prefLabel
Two-weekly or 3-weekly CHOP ch ...... he NHL-B2 trial of the DSHNHL.
@en
Two-weekly or 3-weekly CHOP ch ...... he NHL-B2 trial of the DSHNHL.
@nl
P2093
P1433
P1476
Two-weekly or 3-weekly CHOP ch ...... he NHL-B2 trial of the DSHNHL.
@en
P2093
Alfred C Feller
Christian Rudolph
Christian Rübe
Dieter K Hossfeld
Dirk Hasenclever
German High-Grade Non-Hodgkin's Lymphoma Study Group
Hartmut Eimermacher
Lorenz Trümper
Marcel Reiser
Marita Kloess
P304
P356
10.1182/BLOOD-2003-06-2095
P407
P577
2004-03-11T00:00:00Z